New combo therapy aims to shrink liver tumors enough for surgery
NCT ID NCT07560488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a combination of four treatments—two immunotherapies (ipilimumab N01 and sintilimab), a targeted therapy (bevacizumab biosimilar), and chemotherapy directly into the liver—for people with advanced liver cancer that cannot be surgically removed. The goal is to shrink the tumors enough to allow surgery, potentially improving long-term outcomes. The study enrolls 43 adults aged 18-75 with no prior treatment for their liver cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab N01, sintilimab, bevacizumab biosimilar, and hepatic arterial infusion chemotherapy (FOLFOX-HAIC)
What this could lead to
If successful, this combination could help shrink advanced liver tumors enough to allow surgical removal, potentially offering a chance at long-term control or cure for patients who currently have no surgical options.
What could go wrong
This is an early phase II trial with only 43 participants and no control group, so results may not apply broadly. The combination of multiple drugs also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••